Shattuck Labs, Inc. Stock Price, News & Analysis

Shattuck Labs (NASDAQ: STTK) reported Q3 2025 results and business highlights on Nov 6, 2025. Key points: IND clearance for lead candidate SL-325 in August 2025; first participants dosed in the Phase 1 SAD portion in Q3 2025; enrollment for SAD and MAD expected complete by Q2 2026 with initial data expected by Q2 2026. Shattuck closed a private placement of up to $103 million in August 2025 and says proceeds, assuming full exercise of warrants, are expected to fund operations into 2029. Q3 2025 financials: cash and short-term investments of $86.1M, R&D expense $7.6M, G&A $4.1M, and net loss $10.1M (or $0.14 per share).

Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors, has announced its participation in an upcoming panel discussion following the United European Gastroenterology Week (UEGW) Conference 2025.

The panel will be moderated by Wedbush Securities analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Dr. Marla Dubinsky from Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., Shattuck's CEO, will represent the company at the event scheduled for October 8, 2025, from 10:00 AM to 12:00 PM EST.

Shattuck Labs (NASDAQ: STTK) has announced the closing of a significant private placement of up to $103 million, led by OrbiMed. The funding, assuming full exercise of common stock warrants, is expected to support operations into 2029 and advance SL-325, their novel DR3 blocking antibody, through multiple Phase 2 clinical trials focusing on Inflammatory Bowel Disease (IBD).

The company has also strengthened its Board of Directors with two key appointments: Dr. Daniel Baker, former VP of Immunology at Johnson & Johnson/Janssen, and Dr. Mona Ashiya, Member at OrbiMed. These appointments coincide with the departure of four existing board members, marking Shattuck's strategic repositioning as an immunology and inflammation-focused organization.

Shattuck Labs (NASDAQ: STTK) announced that its Investigational New Drug (IND) application for SL-325, a potentially first-in-class DR3 antagonist antibody for treating Inflammatory Bowel Disease (IBD), is now in effect with the FDA.

The company plans to initiate its Phase 1 clinical trial in Q3 2025, with expected completion in Q2 2026. The trial will be a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses in healthy volunteers. The company's financial position is strengthened by cash reserves and anticipated proceeds of up to $103 million from a recent private placement, expected to fund operations into 2029.

Shattuck Labs (NASDAQ: STTK) reported Q2 2025 financial results and business updates. The company submitted an IND application for SL-325, their first-in-class DR3 blocking antibody for IBD treatment, with FDA clearance expected in Q3 2025. The Phase 1 clinical trial is set to begin in Q3 2025.

Financial highlights include cash position of $50.5 million as of June 30, 2025, and an oversubscribed private placement expected to provide up to $103 million in additional funding. Q2 2025 showed improved financials with net loss of $12.5 million ($0.24 per share), compared to $21.6 million ($0.42 per share) in Q2 2024. The combined funding is expected to support operations into 2029.

Shattuck Labs (NASDAQ: STTK) has secured an oversubscribed private placement expected to raise up to $103 million in gross proceeds. The financing includes initial proceeds of $46 million and potential additional proceeds of $57 million from warrant exercises.

The private placement, led by OrbiMed, involves issuing 15.2M shares of common stock and pre-funded warrants for 37.4M shares at $0.8677 per share, with accompanying warrants for 52.6M shares at $1.0846 exercise price. The proceeds will fund the clinical development of SL-325, a first-in-class DR3 blocking antibody for inflammatory bowel disease treatment, through multiple Phase 2 trials.

The financing is contingent upon IND clearance for SL-325, with the combined proceeds expected to fund operations into 2029.

Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics for inflammatory and immune-related diseases, has announced its participation in the upcoming Leerink Partners Therapeutics Forum. The company's CEO, Dr. Taylor Schreiber, will participate in a panel discussion focused on DR3/TL1A and IBD on July 8, 2025.

The presentation, titled "TL1A: Pioneering a New MOA in IBD and Beyond," will take place at 4:15-5:00 PM ET at the Boston Harbor Hotel. Management will also be available for one-on-one meetings during the conference on July 8-9, 2025.

Shattuck Labs (NASDAQ: STTK) reported its Q1 2025 financial results and business updates. The company's lead product candidate, SL-325, a potential first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), is progressing with an IND filing expected in Q3 2025. The company ended Q1 2025 with $60.9 million in cash, expected to fund operations into 2027. Financial results showed R&D expenses of $9.9 million (down from $16.3M in Q1 2024), G&A expenses of $4.5 million (down from $4.9M), and a net loss of $13.7 million ($0.27 per share). Preclinical studies of SL-325 demonstrated favorable safety profiles, full receptor occupancy at ≥1 mg/kg lasting >28 days, and potential differentiation from TL1A blocking antibodies.

Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.